NDC 63552-0025-02: TOBRAMYCIN SULFATE 1.2 g/30mL Injection, Powder, Lyophilized, For Solution
This is a package of TOBRAMYCIN SULFATE 1.2 g/30mL Injection, Powder, Lyophilized, For Solution from Patheon Manufacturing Services LLC, first listed with the FDA Aug 2001 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 63552-025-02 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 63552 labeler · 025 product · 02 package
- Package marketed since
- Aug 17, 2001
- Package marketing ended
- Nov 30, 2027
- Barcode (UPC-A, from the NDC)
- 3 6355202502 1
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
- It depends on the form. Eye drops and ointment treat eye infections, inhaled forms treat Pseudomonas aeruginosa in cystic fibrosis, and injections treat serious infections. Your pr...
- You breathe it in by mouth, usually twice a day, about 12 hours apart and never less than 6 hours apart. You use it for 28 days, then take 28 days off. Never swallow TOBI Podhaler...
- Inhaled tobramycin commonly causes cough, shortness of breath, sore throat, voice changes and headache. Call your doctor for ringing in the ears, hearing loss, dizziness or wheezin...
- Tell me about everything you take. Drugs that can harm the kidneys, nerves or hearing should be avoided, and furosemide in particular should not be combined with inhaled tobramycin...
Patient education
Drug interactions
Supplement & herbal interactions
Tobramycin may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 63552-0025-01 63552-025-01 Main listing | 72 VIAL, GLASS in 1 CASE / 50 mL in 1 VIAL, GLASS | — | — | Active |
| 63552-0025-02 You're viewing this | 96 VIAL, GLASS in 1 CASE / 50 mL in 1 VIAL, GLASS | — | — | Active |
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of TOBRAMYCIN SULFATE 1.2 g/30mL Injection, Powder, Lyophilized, For Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Tobramycin Sulfate 1.2 g/30mLthis 63552-0025-02 | Patheon | 96 vials | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Tobramycin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Patheon Manufacturing Services LLC labeler code 63552
- COLISTIMETHATE SODIUM 150 mg/6mL Injection, Powder, Lyophilized, For Solution NDC 63552-010-01
- FOSAPREPITANT DIMEGLUMINE 150 mg/5mL Injection, Powder, Lyophilized, For Solution NDC 63552-011-01
- Guanfacine Hydrochloride 1 mg Tablet, Extended Release NDC 63552-021-00
- Guanfacine Hydrochloride 2 mg Tablet, Extended Release NDC 63552-022-00
- Guanfacine Hydrochloride 3 mg Tablet, Extended Release NDC 63552-023-00
- Guanfacine Hydrochloride 4 mg Tablet, Extended Release NDC 63552-024-00
- FERUMOXYTOL NON-STOICHIOMETRIC MAGNETITE 510 mg/17mL Injection NDC 63552-026-01
- Montelukast Sodium 4 mg/.0005kg Granule NDC 63552-027-01
- ETELCALCETIDE HYDROCHLORIDE 2.5 mg/.5mL Solution NDC 63552-029-00
- ETELCALCETIDE HYDROCHLORIDE 5 mg/mL Solution NDC 63552-030-00
- ETELCALCETIDE HYDROCHLORIDE 10 mg/2mL Solution NDC 63552-031-00
- Carfilzomib 30 mg/15mL Injection, Powder, Lyophilized, For Solution NDC 63552-035-00
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Patheon Manufacturing Services LLC supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |